Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788059 | 0.84 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL9911052 | 0.84 | FOLH1 (0.60) | FOLH1 | |
| SCHEMBL19360008 | 0.84 | PRMT1 (0.49) | PRMT1EPHX1FOLH1SMN1; SMN2ADRA1A | |
| SCHEMBL2742770 | 0.82 | FOLH1 (0.48) | PRMT1EPHX1FOLH1SMN1; SMN2ADRA1A | |
| SCHEMBL15275337 | 0.82 | EPHX1 (0.49) | PRMT1EPHX1FOLH1SMN1; SMN2ADRA1A | |
| SCHEMBL19788055 | 0.79 | FOLH1 (0.42) | PRMT1EPHX1FOLH1SMN1; SMN2EPHX2 | |
| SCHEMBL2742756 | 0.79 | FOLH1 (0.42) | PRMT1EPHX1FOLH1SMN1; SMN2EPHX2 | |
| SCHEMBL15828219 | 0.75 | GABRP (0.42) | PRMT1EPHX1FOLH1SMN1; SMN2EPHX2 | |
| SCHEMBL20910851 | 0.74 | FOLH1 (0.66) | FOLH1 | |
| SCHEMBL18538620 | 0.74 | FOLH1 (0.48) | EPHX1FOLH1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125854-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | PFIZER INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9895378-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same | PFIZER INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170266293-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | PFIZER INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170151181-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170119672-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170042828-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170042855-A1 | NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION | BIND THERAPEUTICS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9308179-B2 | Long circulating nanoparticles for sustained release of therapeutic agents | BIND THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160045608-A1 | LONG CIRCULATING NANOPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS | PFIZER INC. | 2016-02-18 | — | — | US | disclosed |
| US-9198874-B2 | Long circulating nanoparticles for sustained release of therapeutic agents | BIND THERAPEUTICS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150258102-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2015-09-17 | — | — | US | disclosed |
| US-20140248358-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249158-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140178475-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | BIND THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130034608-A1 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents | PFIZER INC. | 2013-02-07 | — | — | US | disclosed |
| US-8293276-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248358-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | CD44, NCL, TP53 | PRMT1 1684/4885EPHX1 3285/4885FOLH1 40/4885 |
| US-20150258102-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | TP53, VHL, MTDH | PRMT1 1530/4885EPHX1 3717/4885FOLH1 292/4885 |
| US-20140178475-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | CD44, NCL, TP53 | PRMT1 1684/4885EPHX1 3285/4885FOLH1 40/4885 |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | PRMT1 3790/4885EPHX1 2068/4885FOLH1 177/4885 |
| US-20170119672-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | CD44, NCL, TP53 | PRMT1 1684/4885EPHX1 3285/4885FOLH1 40/4885 |
| US-20140249158-A1 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same | CD44, NCL, TP53 | PRMT1 1684/4885EPHX1 3285/4885FOLH1 40/4885 |
| US-20170266293-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | CD47, NCL, NOP56 | PRMT1 1856/4885EPHX1 4172/4885FOLH1 154/4885 |
| US-20160045608-A1 | LONG CIRCULATING NANOPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS | VEGFA, CD47, CLTA | PRMT1 4085/4885EPHX1 1379/4885FOLH1 1646/4885 |
| US-20180125854-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | TP53, HNRNPH3, VHL | PRMT1 1482/4885EPHX1 3788/4885FOLH1 336/4885 |
| US-20170042828-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | CD44, NCL, TP53 | PRMT1 1684/4885EPHX1 3285/4885FOLH1 40/4885 |
| US-20170151181-A1 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES | KRAS, TP53, NRAS | PRMT1 2506/4885EPHX1 3209/4885FOLH1 336/4885 |
| US-20170042855-A1 | NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION | KRAS, NRAS, HRAS | PRMT1 3362/4885EPHX1 2988/4885FOLH1 1995/4885 |
| US-20130034608-A1 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents | VEGFA, CD47, CLTA | PRMT1 4085/4885EPHX1 1379/4885FOLH1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.